ReviewVeterinary sciences2026
Understanding the Progression of Chronic Kidney Disease in Cats: From Pathophysiology to Emerging Biomarkers.
Review in Veterinary sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Feline chronic kidney disease is a leading cause of mortality in geriatric cats, characterized by a progressive and irreversible loss of renal function. Despite its high prevalence, early diagnosis remains challenging due to nephron compensatory mechanisms and the limited sensitivity of traditional biomarkers, creating a diagnostic gap that necessitates the exploration of novel biomarkers for earlier detection. This review examines the complex pathophysiology of the disease, including renin-angiotensin-aldosterone system activation, tubulointerstitial fibrosis, and mineral metabolism disturbances. By analyzing recent scientific literature, this work evaluates current diagnostic landscape and clinical relevance of emerging biomarkers. Evidence indicates that symmetric dimethylarginine and fibroblast growth factor-23 improve detection of early metabolic and filtration changes, while urinary biomarkers like cystatin B and retinol-binding protein provide specific insights into tubular injury. Bridging the diagnostic gap requires a transition from a reactive, azotemia-based framework to a multi-parametric diagnostic approach that integrates novel biomarkers with serial clinical and laboratory monitoring. Although financial constraints and limited availability restrict widespread clinical implementation, incorporating these advances is essential for earlier prognostic stratification and timely therapeutic decision-making. This integrated strategy has the potential to slow disease progression and improve survival and quality of life in cats with chronic kidney disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.